Home Tags Platinum Resistant Ovarian Cancer

Tag: Platinum Resistant Ovarian Cancer

Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

ASCO 2022: SORAYA Study Shows Consistent Safety Profile for Mirvetuximab Soravtansine...

Mirvetuximab soravtansine, previously know as IMGN853, shows a tumor reduction in 71.4% of patients and preliminary median overall survival of 13.8 months in high folate receptor...

Elucida Submits IND for ELU-001 for the Treatment of Cancers Overexpressing...

Pioneering the next frontier in targeted cancer therapy, the Elucida Oncology confirmed that it has submitted an Investigational New Drug Application (IND) to the...

ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine

Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...

FORWARD I Phase III Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian...

The FORWARD I Phase III registration trial (NCT02631876) evaluating the antibody-drug conjugate or ADC mirvetuximab soravtansine as a single-agent therapy for the treatment of...

Encouraging Data for Novel ADC Presented at ESMO 2016

During the annual meeting of the European Society for Medical Oncology (ESMO) being held October 7 – 11, 2016 in Copenhagen, Denmark, preliminary data for PF-06647020...

X